Investorideas.com - Biotech/Pharma Sector Trading Snapshot; (NASDAQ: BPAX), (NASDAQ: CADX), (NASDAQ:SUPG), (OTCBB: UVFT)
Point Roberts, WA –October 27, 2010 (Investorideas.com Newswire and www.biotechindustrystocks.com) - InvestorIdeas.com, a leader in sector research tools for investors, features a Biotech /Pharma Sector Trading Snapshot, as of the close October 26th. Bullish trading in some of the stocks included SuperGen, Inc.(NasdaqGM: SUPG), one of the top advancing stocks on the NASDAQ, closing at $2.82, up $ 0.49 (21.03%), followed by additional gains in after market trading.
Biotech /Pharma Sector Trading Snapshot: (as of close October 26th)
BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) closed at $1.57, up 0.01 (0.64%), trading as high as $1.59 on the day.
Cadence Pharmaceuticals Inc. (NASDAQ: CADX) closed at $8.9, up 0.24 (2.75%) on 445,648 shares.
SuperGen Inc. (NASDAQ:SUPG) closed at $2.82, up $ 0.49 (21.03%) on over 3.4 million shares.
UV Flu Technologies, Inc. (OTCBB: UVFT) closed at $0.3850, up 0.0250 (6.94%) on over 1.3 million shares.
Biotech/Pharma Stocks Recent News;
BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) News:
BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) Reports Positive LibiGel® Data Monitoring Committee Recommendation
No safety issues observed, study to continue as per protocol without modifications
LINCOLNSHIRE, Ill. - October 25, 2010 (Investorideas.com newswire) BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced that the Phase III LibiGel (testosterone gel) cardiovascular and breast cancer safety study will continue without modifications and will continue to enroll new subjects as a result of the fourth unblinded review of adverse events and the first unblinded statistical analysis for sample-size determination by its independent Data Monitoring Committee (DMC). The review and statistical analysis were based on 2,500 subjects who have been enrolled in the study. LibiGel is in development for the treatment of female sexual dysfunction (FSD), specifically, hypoactive sexual desire disorder (HSDD) in menopausal women, for which there is currently no FDA approved product.
Full news: http://www.investorideas.com/CO/BPAX/news/10252.asp
More news - Visit the BPAX showcase profile at Investorideas.com
Disclosure, Disclaimer/ BPAX is a paid advertising client on Investorideas.com
UV Flu Technologies, Inc., (OTCBB: UVFT) News
UV Flu Technologies (OTCBB: UVFT) Featured in MWMarketMovers.com Analyst Report; Carried in Wednesday's Wall Street Journal
Analyst Report by Michael Williams; Published in Wall Street Journal, October 27, 2010
New York, NY – October 26, 2010 (Investorideas.com Newswire) - Biotech News Update: A 12-page analyst report on UV Flu Technologies, Inc. (OTCBB: UVFT) will be carried by The Wall Street Journal as an advertising insert in the October 27th edition of the paper. The Wall Street Journal is published by Dow Jones, a world-class publisher of financial and business newspapers, newswires, indexes, magazines, and more. The report has been authored by Michael Williams Market Movers and can also be found online by visiting www.MWMarketMovers.com.
Full news: http://www.investorideas.com/CO/UVFT/news/10261.asp
More news - Visit the UVFT showcase on Investorideas.com
Disclosure, Disclaimer/ UVFT is a paid advertising client on Investorideas.com
SuperGen, Inc. (NASDAQ:SUPG) News:
SuperGen Reports 2010 Third Quarter Financial Results
Dacogen Royalty Revenue Increases 28% from Same Prior Year Quarter Increases Annual Royalty and Net Income Guidance for 2010
DUBLIN, Calif.—October 25, 2010 - SuperGen, Inc. (NASDAQ:SUPG ) today reported financial results for the third quarter and nine months ended September 30, 2010.
“The third quarter was another profitable one for SuperGen. Royalties from Dacogen sales increased significantly, and we ended the quarter with more than $112 million in unrestricted cash, cash equivalents and current and non-current marketable securities, and no debt. As a result, we have raised both our royalty revenue and net income guidance for 2010,” said James S.J. Manuso, Ph.D., President and CEO. “We continue to advance the development of our drugs in the clinic, and SGI-110, a novel, second-generation DNA methylation inhibitor, is on schedule to enter a first-in-human clinical trial in myelodysplastic syndromes and AML during November.”
Full News; http://finance.yahoo.com/news/SuperGen-Reports-2010-Third-bw-1951926175.html?x=0&.v=1
Research other biotech stocks at the Biotech stocks Directory: http://www.investorideas.com/BIS/Stock_List.asp
InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector investing, covering leading industry sectors including mining and gold stocks, in addition to global markets including China, India, the Middle East and Australia. Investorideas.com is known for its comprehensive stock directories in each sector and sector specific newswires.
Sign up for free stock alerts on biotech stocks and other leading sectors!
About our Biotech investor portal:
www.BiotechIndustryStocks.com is a global meeting place for investors and industry following the biotech and pharma sector, within Investorideas.com. Global visitors use the site daily to research the latest news, articles, audio, research reports and our stock directories.
Disclaimer/disclosure : The following news is sponsored for by showcase stocks BPAX and UVFT ( third party on behalf of UV Flu- three thousand per month and three thousand per month BPAX) Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of principal. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
C Van Zant: 800-665-0411 - email@example.com
Source - Investorideas.com